Mednet Logo
CommunityMedical Oncology

Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?

Would you use MRD status to guide your decision making?
Community PollStarted

How do you manage maintenance for transplant-ineligible myeloma on VRd?

90 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on

Excellent question without a clear answer. While several RCTs have looked at post-induction maintenance among patients without planned transplantations, the British Myeloma XI trial is the biggest RCT (to my knowledge) to clearly look at lenalidomide vs observation in transplant-ineligible patients....

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · NYU Long Island School of Medicine
Answered on

When it comes to maintenance, I am more of a purist in terms of following the protocol as was done in the clinical trials. Therefore, I typically discontinue bortezomib after 8 cycles for transplant-ineligible patients, particularly to avoid neuropathy and myelosuppression. One could also rechalleng...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on

Yes, I would continue with Vand R as long as they are tolerated. I often change the V to every other week past the initial 8 cycles.

Join for free or sign in to see the full answer